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Summary
The mammalian T cell receptor (TCR) orchestrates immunity by responding
to many billions of different ligands that it has never encountered before
and cannot adapt to at the protein sequence level. This remarkable receptor
exists in two main heterodimeric isoforms: ab TCR and gd TCR. The ab
TCR is expressed on the majority of peripheral T cells. Most ab T cells
recognize peptides, derived from degraded proteins, presented at the cell
surface in molecular cradles called major histocompatibility complex (MHC)
molecules. Recent reports have described other ab T cell subsets. These
‘unconventional’ T cells bear TCRs that are capable of recognizing lipid
ligands presented in the context of the MHC-like CD1 protein family or
bacterial metabolites bound to the MHC-related protein 1 (MR1). gd T cells
constitute a minority of the T cell pool in human blood, but can represent
up to half of total T cells in tissues such as the gut and skin. The identity
of the preferred ligands for gd T cells remains obscure, but it is now
known that this receptor can also functionally engage CD1-lipid, or
immunoglobulin (Ig) superfamily proteins called butyrophilins in the
presence of pyrophosphate intermediates of bacterial lipid biosynthesis.
Interactions between TCRs and these ligands allow the host to discriminate
between self and non-self and co-ordinate an attack on the latter. Here, we
describe how cells of the T lymphocyte lineage and their antigen receptors
are generated and discuss the various modes of antigen recognition by these
extraordinarily versatile receptors.
Keywords: CD1, MHC-I, MHC-II, MHC-Ib, MR1, T cell, T cell receptor,
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Introduction
Immune surveillance by T lymphocytes is critical for the
immune integrity of all jawed vertebrates and is imposed
through an intricate armoury of functions that eliminate
pathogen-infected and neoplastic cells. The T cell pool
consists of several functionally and phenotypically hetero-
geneous subpopulations. T cells are broadly classified as
ab or gd according to the somatically rearranged T cell
receptor (TCR) they express at their surface.
ab T cells are by far the most abundant and the best-
characterized circulating T cells. Most ab T cells recognize
peptides from degraded proteins bound to major histocom-
patibility complex (MHC) molecules at the cell surface.
These peptide-MHC (pMHC)-recognizing T cells were the
first to be described [1]. T cells that respond to pMHC are
said to be ‘conventional’. However, a significant fraction of
the ab T cell pool consists of rarer T lymphocytes that do
not recognize pMHC. These ‘unconventional’ ab T cells
include: (i) mucosal-associated invariant T (MAIT) cells
that display limited diversity and are involved in anti-
bacterial immunity [2,3]; (ii) invariant natural killer T
(iNK T) cells; and (iii) germline-encoded mycolyl-reactive
(GEM) T cells. iNK T and GEM T cells are dedicated to
recognition of glycolipids in the context of CD1d and
CD1b, respectively [4,5]. Other T cells are believed to recog-
nize lipid antigens in the context of CD1a and CD1c, but
these subsets have not been well characterized, or named, at
the time of writing.
gd T cells are also grouped as being ‘unconventional’, as
they are not MHC-restricted and do not appear to recognize
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peptide antigens. One to 10% of circulating T cells express a
gd TCR, but this fraction is considerably higher in epithelial
tissues. These tissues form the main portal of entry for patho-
gens, suggesting an important role of gd T cells as early
immune sentinels. Murine knock-out studies have demon-
strated that gd T cells have a clear role in pathogen clearance
and tumour surveillance [6]. Some T cells express a d/ab
TCR hybrid. This is because the recombination mechanism
used to generate TCR chains operates on the same locus for
TCR-d and TCR-a. Thus, some gene segments within the
locus can, in some instances, be involved in the generation of
TCR chains that are partially a and partially d and are able to
pair with canonical TCR-b chains [7]. These so-called d/ab
T cells constitute a significant proportion of T cells that rec-
ognize the CD1d-a-galactosylceramide (aGalCer) complex
[7]. Other hybrid TCRs further blur traditional segregation
into ab and gd TCRs, as VgJb, VbJg, VdJb, VdJg and VgJd
TCR chains have been described, with or without the inclu-
sion of Db and Dd segments. Many of these combinations
follow the 12/23 rule of V–(D)–J recombination, are tran-
scribed into full transcripts and translated into hybrid
proteins [8]. The antigens recognized by T cells bearing
these non-canonical TCR chains remain unknown, although
a subset of Vg (Db) Jb TCRs are reported to be MHC-
restricted [9].
Despite the functional and phenotypical differences
between subsets, all T cells arise from the same precursors
and share their early differentiation history. Thymic pro-
genitor cells seed the thymus from the fetal liver or adult
bone marrow. In the thymus, these progenitors enter a
complex differentiation programme which leads to irre-
versible acquisition of T cell identity and expression of
clonally distributed, variegated TCRs. In this review, we
describe the mechanisms through which MHC-restricted
and MHC-independent TCRs are generated and discuss
recognition of antigen by distinct T cell subsets. We also
re-examine recent findings on the more ‘unconventional’
subsets.
Generation of diversity and thymic selection
TCR diversity is generated somatically by gene rearrange-
ment, a process that allows a vast array of different recep-
tors to be produced from a limited set of genes. At the
TCR-a locus (tra), discrete variable (V) and junctional
(J) gene segments are recombined and juxtaposed to a
constant (C) segment (Fig. 1a). Recombination at the
TCR-b locus (trb) is similar, but includes an additional
diversity (D) segment and one of two C segments can be
appended to the rearranged TCR-b chain (Fig. 1b). The
variability of TCRs is confined predominantly to three
short hairpin loops on each chain, called complementar-
ity determining regions (CDR). Collectively, the six CDR
loops sit at the membrane-distal end of the TCR extracel-
lular domain to form the antigen-binding site (Fig. 2a).
The variable CDR1 and 2 loops are encoded in the germ-
line by the T cell receptor alpha variable (TRAV) and T
cell receptor beta variable (TRBV) gene segments. By con-
trast, the hypervariable CDR3 loops are generated by ran-
dom deletion and addition of template and non-template
nucleotides at the junction between recombining V, (D)
and J gene segments (Fig. 2b). Polymorphism in the tr
loci could add yet further diversity to the potential TCR
repertoire at the population level [12]. Theoretically, gene
rearrangement by V–(D)–J recombination alone can pro-
duce 1018 TCRs in humans [13] and 1015 TCRs in the
mouse [14]. gd TCRs are also generated by V–(D)–J
recombination (Fig. 1c,d). The TCR-d chain is thought to
be by far the most diverse TCR chain due to the inclu-
sion of multiple D segments, which can be translated in
any reading frame (Fig. 2b). Thus, the theoretical number
of different gd TCRs that could be produced is potentially
much greater than for the ab TCR.
The quasi-random process of generating ab TCRs
described above has the capacity to generate receptors
that are inept at recognizing self-MHC molecules and
receptors that could be autoreactive. Thymic selection
ensures that only T cells bearing a TCR that recognizes
self-peptides in the context of self-MHC receive a survival
signal. The majority of thymocytes do not receive this sig-
nal. Cells that express TCRs that cannot recognize self-
pMHC are unlikely to be useful for recognizing foreign
peptides. These cells do not receive a survival signal
through their TCR and are said to ‘die by neglect’. At the
other extreme, thymocytes that bear TCRs that react
strongly to self-pMHC have the capacity to be autoreac-
tive and are culled through a process of negative selec-
tion. Together, positive and negative selection ensure that
only those ab T cells that are restricted to recognizing
self-pMHC within a low affinity range can populate the
periphery. Thus, the thymic environment allows the gen-
eration of a pool of ab T cells that are self-restricted, but
not self-reactive [15].
Much less is known about selection of other, MHC-
independent, T cell subsets. Invariant (type I) NK T cells
are selected on CD1d-expressing CD41CD81 double-
positive thymocytes and acquire effector function before
exiting the thymus [16–18]. Selection of MAIT cells has
been shown recently to require MR1 expression on
double-positive thymocytes [19]. Commitment to the gd
T cell fate is thought to be a TCR-dependent process
whereby strong gd TCR signals induce gd commitment
and weak pre-TCR signals, in the absence of gd TCR sig-
nalling, instruct thymocytes to initiate tra rearrangement
[20]. This model mirrors classic positive selection via the
ab TCR and suggests that gd T cells may also need to
encounter a cognate ligand in the thymus. Indeed, CD73
is up-regulated as a result of gd TCR activation in the
thymus. As CD73 is expressed by the majority of periph-
eral gd T cells, ligand recognition in the thymus appears
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to be a common occurrence during gd T cell develop-
ment [21]. However, potential ligands for gd T cells are
largely unknown. Skint-1 is the only known ligand
required for maturation of Vg51 dendritic epidermal gd
T cells in the mouse, although its role in selection
remains controversial [22]. Interestingly, a study of
murine T10/T22-reactive gd T cells has indicated that, in
contrast to ab T cells, ligand recognition by the gd TCR
imprints effector function on the gd T cell pool, but not
antigen specificity [23]. Overall, gd T cell selection is
poorly understood and the identity of potential positive
selection ligands for gd TCRs continues to be a matter of
debate.
Conventional, pMHC-restricted T cells
The cardinal feature of ab T cells is the recognition of
peptides derived from self and foreign proteins in the
context of self-MHC molecules. The mhc locus was first
described more than half a century ago as the set of genes
which determine the outcome of tissue transplantation in
congenic mice. It is now clear that the products of the
mhc have evolved to allow T cells to perform highly spe-
cific functions which are crucial to adaptive immunity
and host defence as a whole. The mhc locus is the most
gene-dense and the most polymorphic region known to
date, with more than 12 000 different alleles already
Fig. 1. Generation of ab and gd T cell receptors (TCRs) by V–(D)–J recombination. (a) The tra/trd locus consists of a cluster of 46 functional T
cell receptor alpha variable (TRAV) segments and eight T cell receptor delta variable (TRDV) segments, followed by three segments in the T cell
receptor delta diversity (TRDD) cluster and four segments in the T cell receptor delta joining (TRDJ) cluster. A total of 51 functional TRAV
segments lie between the TRDC and the T cell receptor alpha chain constant region (TRAC) segments. At the tra/trd locus, V–J recombination
brings together one of many TRAV segments and one of many TRAJ segments. The intervening sequences are spliced out, producing a TCR-a
transcript in which V, J and C segments are directly adjacent. (b) The trb locus comprises 48 functional T cell receptor beta variable (TRBV)
segments followed by two D segments, 12 functional TRBJ segments and two TRBC segments. For TCR-b chain rearrangements, V–(D)–J
recombination is a two-step, ordered process. D–J recombination occurs first, juxtaposing TRBD1 to one of many TRBJ1 segments or TRBD2 to
one of many TRBJ2 segments. V–DJ recombination subsequently brings the rearranged DJ join to one of many TRBV segments. The intervening
sequences are then spliced out, generating a TCR-b transcript in which V, D, J and C segments are directly adjacent. (c) The trg locus is
composed of six functional TRGV segments and five TRGJ segments followed by two TRGC segments. At the trg locus, V–J recombination joins
one of many TRGV segments to a TRGJ segment. Similar to TCR-a chains, the intervening regions are spliced, producing a TCR-g transcript in
which V, J and C segments are directly adjacent. (d) The generation of TCR-d chains also occurs at the tra/trd locus. The 50 end of this locus
consists of a cluster of V genes. All V genes in this cluster can recombine with TRAJ, but only a subset can recombine with TRDD. Thus, many
V genes in the tra/trd locus are used exclusively for TCR-d rearrangement in early thymic precursors, while others are used exclusively for TCR-a
rearrangement in double-positive thymocytes. Some V genes can be used interchangeably. Similar to TCR-b chains, TCR-d chains are produced
by V–(D)–J recombination and splicing, producing a final transcript in which V, D, J and C segments are directly juxtaposed. Unlike the TCR-b
chain, however, TCR-d can incorporate multiple D segments.
T cell receptor versatility
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described in humans [24]. Polymorphism at the mhc
ensures diversity in peptide presentation at the popula-
tion level.
There are two types of classical MHC molecules: MHC
class I (MHC-I) and MHC class II (MHC-II). There are
three classical human MHC-I genes [human leucocyte
antigen (HLA)-A, -B and -C]. These genes encode a
membrane-spanning a-chain associated with the non-
polymorphic b2 microglobulin (b2m) protein (Fig. 3a).
Polymorphism is confined mainly to the membrane-distal
a1 and a2 domains, while the a3 domain is largely invar-
iant. The human MHC-II genes (DP, DQ and DR)
encode two distinct polymorphic a and b-chains. Each
chain folds into a membrane-distal polymorphic domain
followed by a membrane-proximal immunoglobulin (Ig)-
like domain (Fig. 3d) [37]. The peptide-binding cleft of
both MHC-I and MHC-II consists of two anti-parallel a-
helices forming a channel in which the peptide can bind
in an extended conformation on a platform of eight anti-
parallel b-pleated sheets. Specific peptide-binding pockets
in the base of this cleft vary between different MHC
alleles [38]. The binding affinity for MHC differs between
peptides according to their primary sequence. A given
peptide will, at best, bind a limited set of MHCs. Recip-
rocally, any MHC allele can only accommodate a small
fraction of the peptide collection derived from a given
protein.
Conventional ab TCR ligands
MHC-I molecules are expressed on nearly all nucleated
cells and present peptides derived from endogenous pro-
teins, allowing T cells to interrogate the internal proteome
by scanning the surface of the target cell. MHC-II mole-
cules differ from MHC-I in that they predominantly pres-
ent peptides derived from exogenous proteins and are
expressed primarily on professional antigen-presenting
cells. Despite the similarities in overall conformation (Fig.
3), MHC-I and MHC-II present peptides in a distinct
manner governed by the configuration of the peptide-
binding cleft. Polymorphic residues define the size and
chemical properties of the binding pockets within the
cleft and therefore the peptide collection that can be
accommodated by a given MHC-I molecule. The closed
Fig. 2. Structure of T cell receptor (TCR) proteins and mRNA. (a) ab [Protein Data Bank (PDB): 3HG1] [10] and gd (PDB: 1HXM) [11].
TCRs adopt similar tertiary structures that position the complementarity-determining regions (CDR) loops at the membrane distal end of the
molecules. Together the six CDR loops form the antigen binding site. (b) The mRNA structures show that for each chain CDR1 and CDR2 are
encoded in the germline. CDR3 is the product of junctional diversity at V–J joins of T cell receptor (TCR)-a and TCR-g chains and V–D–J joins
in TCR-b and TCR-d chains. CDR3 is consequently hypervariable. The colour code adopted for the CDR loops is maintained throughout this
paper. The areas coloured in grey represent the constant and variable domains of the TCRs (not including the hypervariable CDR loops).
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conformation of the MHC-I a1a2 binding cleft (Fig. 3b)
restricts the length of peptides that can be accommo-
dated. MHC-I molecules typically bind peptides of eight
to 10 amino acids in length, but longer peptides have
been observed in some instances [39]. Because the MHC-
I peptide-binding groove is closed at both ends, long pep-
tides bulge out (Fig. 3c), exposing peptide side chains for
direct interaction with the TCR [39]. Curiously, our own
recent studies have shown that MHC-I restricted TCRs
appear to be predisposed to bind peptides of a defined
length [27]. In contrast, the MHC-II peptide-binding
groove is an open-ended conformation (Fig. 3e) which
allows the binding of N- and C-terminally extended pep-
tides of up to 30 amino acids in length (Fig. 3f).
TCR recognition of pMHC
MHC restriction is a defining characteristic of ‘conven-
tional’ ab T cells. Although MHC restriction was
described more than 30 years ago, the molecular forces
Fig. 3. The structures of peptide-major histocompatibility complex class I (pMHC-I) and class II (pMHC-II). The two classes of classical MHC
adopt similar overall structures despite being differently comprised. MHC-I [Protein Data Bank (PDB): 1ZHL] [25] (a) consists of a variable
heavy chain (grey) folded with the invariant b-2-microglobulin molecule (cyan). (b) The ends of the MHC-I peptide-binding groove are closed.
MHC-I presents peptides of 8–14 amino acids in length to T cells. (c) An 8-mer peptide can lie flat in the MHC-I groove. As additional amino
acid residues are added, peptides have to bulge upwards and outwards in order to be accommodated within the groove. It has recently been
established that MHC-I restricted T cells can recognize the length of a peptide in addition to its amino acid sequence (PDB: 1ZHL, 1XH3, 2FZ3,
3BW9, 1A1N, 1JF1, 1HHI) [25,27–33], whereas MHC-II (PDB: 1KG0) [26] (d) consists of an a-chain (grey) and a b-chain (cyan). Both MHC-I
and MHC-II fold to present peptide (red) to T cells within a peptide-binding groove. (e) The open ends of the MHC-II peptide-binding groove
allow presented peptides to extend at both the N- and C-terminus. Thus, MHC-II generally presents longer peptides than MHC-I. This mode of
binding also means that the MHC-II can sometimes present the same peptide in different registers by using different amino acid side chains for
anchoring into the MHC-binding pockets. (f) The open-ended MHC-II binding groove enables longer peptides to form an elongated
conformation with peptide N- and C-terminal peptide flanking regions extending outside of the groove (PDB: 1KG0, 1UVQ, 2SEB, 2IAN)
[26,34–36].
T cell receptor versatility
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driving this interaction are still fiercely debated. Struc-
tural analyses of TCRs in their free and MHC-bound
states have established that the TCR–pMHC interaction
conforms to some ‘rules of engagement’. Indeed, most
TCRs bind pMHC in a diagonal or nearly orthogonal ori-
entation relative to the long axis of the MHC peptide-
binding groove (Fig. 4a and b) [37]. This conserved
docking strategy, together with the observation that 20%
of the pre-selection TCR repertoire is MHC-specific [42],
has led to the idea that TCRs are genetically ‘hard-wired’
for MHC recognition [23–45]. These rules fit conven-
iently with the observation that the germline-encoded
CDR1a, CDR1b, CDR2a and CDR2b often contact the
MHC a-helices, whereas the somatically rearranged
CDR3a and CDR3b loops contact the peptide (Fig. 4c).
This dogma was long supported by the identification of
the so-called ‘interaction codons’ and the amino acids
defining the MHC-I ‘restriction triad’ [44,46]. More
recently, however, Stadinski et al. [47] challenged the
germline theory by demonstrating that the putative ‘inter-
action codons’ in a murine TCR-b chain were not strictly
conserved, but were largely dependent on the identity of
the partner TCR-a chain. Mutational studies on MHC
alleles also suggest that TCR–pMHC interactions allow
for substantial plasticity within the confines of a common
binding and orientation system [48]. A murine study in
which CDR1 and CDR2 were randomized in vivo in the
context of a fixed CDR3 failed to show preferential selec-
tion for the wild-type CDR1 and 2 sequences, contradict-
ing the idea of TCRs being genetically ‘biased’ towards
MHC ligands [49]. It remains possible that the semi-
conserved angle and polarity of TCR–pMHC interaction
is required for the correct orientation of intracellular sig-
nalling domains, the positioning of the co-receptor bind-
ing site on MHC relative to the TCR or imposed by
extracellular sites of glycosylation, as indicated by the
Fig. 4. T cell receptor (TCR)–peptide-major histocompatibility complex (pMHC) structures. MHC molecules (in grey) and peptide (in red
sticks) are overlaid with the docking footprints of the individual complementarity-determining regions (CDR) loops of the cognate abTCR. The
coloured footprints correspond to the colours of the CDR loops shown in Fig. 2. (a) Structure of MHC-I molecule HLA-A*0201 presenting the
immunodominant GLCTLVAML peptide from Epstein–Barr virus (EBV) [Protein Data Bank (PDB): 3O4L] [40]. The coloured footprint shows
how the CDR loops of the AS01 TCR sit on the pMHC complex. This complex adopts a canonical conformation where the germline-encoded
CDR1 and 2 loops contact mainly the MHC and the hypervariable CDR3 loops sit over the peptide. (b) Structure of the MS2-3C8TCR docked
on the MHC class II molecule human leucocyte antigen (HLA)-DR4. Here, HLA-DR4 presents a peptide from myelin basic protein (PDB: 3O6F)
[41]. (c) Overlay of all MHC-I (grey cartoon and surface)-restricted TCRs (multi-coloured) in which co-complex structures have been solved. All
complexes were aligned on the MHC-I molecule to demonstrate the flexible nature of TCR–pMHC binding.
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crystal structure of a ternary TCR–pMHC–CD4 complex
[50]. Our recent studies show that TCR-peptide specific-
ity overrides affinity-enhancing TCR–pMHC interactions
to suggest that TCR CDR3 loops might need to ‘accept’
peptide prior to TCR engagement the MHC component
of the ligand [51]. Further work is required in order to
dissect the sequence of molecular events involved in
TCR–pMHC binding.
An alternative to the germline theory of MHC restric-
tion suggests that recognition of MHC-restricted ligands
is the result of a selection process through which the
peripheral repertoire is enriched with MHC-specific TCRs
and purged of MHC-independent TCRs. In a series of
studies involving MHC-I, MHC-II and co-receptor defi-
cient-mice (referred to as ‘quad-deficient’ mice), it was
shown that the selection of MHC-specific TCRs was
strictly governed by the T cell co-receptors CD4 and
CD8. CD4 and CD8 act as antigen co-receptors by bind-
ing to invariant regions of the MHC-II and MHC-I,
respectively, at sites distinct from the TCR docking plat-
form (Fig. 5). The cytoplasmic tail of the co-receptor
binds to the protein tyrosine kinase Lck, which mediates
key membrane-proximal phosphorylation events during T
cell activation and selection. Singer and colleagues [53]
first showed that the deletion of both co-receptors
allowed selection of CD41 and CD81 T cells to take place
on an MHC-deficient background. The authors worked
on the premise that co-receptor-independent signalling
can occur and is initiated by non-MHC ligand binding to
the TCR, akin to cross-linking antibodies. By contrast, in
the presence of co-receptors, which sequester all the avail-
able Lck needed for signalling, TCR signalling can be trig-
gered only by MHC ligands. Thus, in the ‘quad-deficient’
mouse, non-MHC ligands can induce thymic selection of
MHC-independent T cells – T cells which would other-
wise die by neglect in a normal thymus [54–56]. Reports
of MHC-independent ligands for ab T cells are scarce in
the literature, although a number of examples have been
observed in the mouse [57] and in humans [58,59]. The
existence of MHC-independent ab TCRs in the periphery
further supports the notion that MHC restriction is a
TCR-extrinsic feature imposed on developing thymocytes
through thymic selection.
ab TCR cross-reactivity
As described above, the mhc locus is an example of
extreme polymorphism. The vast majority of polymor-
phic residues in MHC proteins cluster around the
peptide-binding cleft to suggest that this diversity is
upheld to expand the variety of peptides that can be dis-
played to the immune system [38]. The TCR must recog-
nize peptides presented by all these variants. Beyond this,
effective T cell immunity requires the TCR repertoire to
recognize virtually any foreign peptide that can bind to
host MHC molecules as a failure to recognize all possible
foreign peptides would leave ‘blind spots’ that could be
exploited by pathogens [60]. Unlike the B cell receptor,
the protein sequence of the TCR is fixed and never
undergoes affinity maturation, so the TCRs expressed on
existing naive T cells must be capable of responding to all
alien antigens, despite never having encountered them
before and being unable to adapt to them. The size of
this task becomes apparent once it is realized just how
many potential foreign peptides there are. This major
evolutionary challenge has been met by enabling each
Fig. 5. CD8 and CD4 co-receptors bind to invariant parts of peptide-major histocompatibility complex class I (pMHC-I) and pMHC-II,
respectively. (a) Structural model of a T cell receptor (TCR)–pMHC-I–CD8 tripartite interaction [Protein Data Bank (PDB): 3O4L and 1AKJ]
[40,52]. MHC-I (grey cartoon) forms the peptide binding cleft using its a1 and a2 domains. The membrane distal face of the molecule
comprises the TCR (blue and slate cartoon) docking platform. CD8 (green and yellow cartoon) binds at a distinct site on the a3 domain of the
molecule. The structure shown is human leucocyte antigen (HLA) A*0201 and a CD8aa homodimer [52]. (b) Tripartite complex structure of
the TCR–pMHC-II–CD4 interaction (CD4 shown in orange cartoon) (PDB: 3T0E) [50]. Similar to the TCR–pMHC-I–CD8 model, the CD4 co-
receptor binds to an invariant site distal from the TCR binding platform.
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TCR to interact with many – sometimes millions – of
individual peptides bound in the groove of a single MHC
[13,61]. TCRs are further capable of engaging peptides
presented by different foreign MHC alleles to promote
alloreactivity. This enormous receptor plasticity is
bestowed via a number of different mechanisms, as TCR
binding can vary from being rigid and very focused [62]
to being flexible in terms of both binding register and
individual CDR loops (Fig. 6). It is also possible that the
ability of T cells to respond to different TCR ligands
could be varied during T cell development. TCR engage-
ment in the presence of inhibitory signals is likely to
dampen the number of ligands, whereas co-stimulatory
signals would be expected to generate a greater level of T
cell sensitivity and might increase the number of ligands
that could be recognized (Fig. 7a,b). The co-receptors,
CD8 and CD4, fall into a class of their own by co-
engaging the pMHC ligand, thereby generating capacity
for the molecules to alter which TCR ligands a T cell can
respond to [66,67] (Fig. 7c).
Implications of T cell cross-reactivity
It is becoming apparent that effective immune cover
requires that each TCR must allow the T cell that bears it
to respond to a large array of different peptide ligands
[60]. This extensive receptor cross-reactivity has a num-
ber of important consequences. First, it allows a relatively
small number of TCRs (25 million [68]) to provide
effective immune cover for a vastly greater number of
theoretical foreign peptides that could be encountered.
Extensive T cell cross-reactivity also ensures that far fewer
T cells are required to scan a cell displaying a foreign
peptide before one reacts to this peptide, thus ensuring a
more rapid response time. The corollary of far-reaching
TCR cross-reactivity is that each peptide will be
Fig. 6. The plasticity of ab T cell receptor (TCR)
binding to peptide-major histocompatibility
complex (pMHC). Individual TCRs use multiple
mechanisms to bind to pMHC. These effects can
increase the number of individual peptides that
can be recognized. (a) Macro-level changes enable
the TCR to bind pMHC with an altered angle or
altered register. The cartoon shows the ‘footprints’
of TCR complementarity-determining region
(CDR) loops projected down onto the pMHC. (b)
Relatively micro-level flexibility in the CDR loops
allows them to accommodate a variety of different
shapes. The cartoon shows a side view of a TCR
engaging pMHC. (c) The existing database of
TCR–pMHC structures indicates that TCRs tend
to focus interaction on two to four upward-facing
amino acid residues in the antigenic peptide (so-
called ‘hotspots’ [63]). In this example a TCR
might focus on two amino acids in the peptide
(shown in red). Such residue-focused interaction
then allows the TCR to accommodate multiple
amino acid substitutions at other positions in the
peptide (indicated by the use of different colours
on the right). The three mechanisms described
above are not mutually exclusive and represent
just some of the possibilities. Many residues can
also bind in individual MHC binding pockets. It
is now understood that altering a primary MHC
anchor can substantially change the way that a
peptide might be viewed by incoming T cells
[64,65].
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recognized by several different receptors (i.e. T cell
responses are polyclonal). Escape from a polyclonal T cell
response represents a far greater challenge for pathogens
that can vary their antigens, as a mutation that escapes
from one TCR may still be recognized by a different
TCR. Heterologous immunity, where a single T cell can
respond to several infections, is a further important con-
sequence of individual TCRs being capable of responding
to multiple peptides [69]. Once it is realized that T cells
can respond to many different peptides it should come as
little surprise that there are pre-existing populations of
HIV-specific memory T cells in people who are unin-
fected with this virus [70]. The extent and implications
of T cell heterologous immunity are described in detail
elsewhere [13,69]. The advantages of having a broadly
cross-reactive T cell repertoire must outweigh the nega-
tives, or the system would have been expected to evolve
differently. Nevertheless, it is believed that widely cross-
reactive T cells can have detrimental consequences. Most
notably, the concept of T cells becoming activated by
pathogens and then cross-recognizing self-ligands – a
phenomenon known as molecular mimicry [71] – is
believed to be the root cause of autoimmune disease (Fig.
8). A further important consequence of TCR binding
plasticity is alloreactive recognition of non-self-HLA pre-
senting self-peptide because such recognition causes acute
rejection of HLA-mismatched grafted organs [72]. Allor-
eactive recognition of pMHC by the TCR represents the
major barrier to organ transplantation. Most transplants
are HLA mismatched and require that the recipient take
lifelong immunosuppressive medication, with its associ-
ated expense and side effects.
Therapeutic use of the ab TCR
The transfer of TCR genes into recipient host T cells fol-
lowed by the adoptive transfer of these cells to patients
allows the passive transfer of immunity [73]. This strategy
can provide a convenient means for breaking tolerance to
tumour antigens and has already shown promise in
patients with malignant melanoma [74]. As described
above, T cell immunity is a compromise where a limited
number of receptors are required to provide immune
cover for a vastly greater number of potential foreign
Fig. 7. The peptide cross-reactivity of
conventional T cells can be varied. In order to be
positively selected in the thymus, a T cell must
bear a T cell receptor (TCR) that allows it to
recognize – and respond to – self-peptide. It
should not respond to this peptide thereafter. T
cell cross-reactivity could be regulated throughout
the lifetime of a T cell. (a) Co-inhibitory (in red)
or (b) co-stimulatory signals (in green) are likely
to decrease and increase the number of ligands
that can be recognized by tuning the sensitivity of
TCR engagement that a T cell responds to. (c)
The co-receptors, CD4 and CD8 (in purple),
represent a special class of co-stimulation as these
receptors bind to the same peptide–major
histocompatibility complex (pMHC) ligand at the
TCR. This could allow the co-receptors to
discriminate between different TCR–pMHC dwell
times and thus tune a T cell to recognize only
certain ligands [66]. Regulation of the cell surface
expression and/or glycosylation of key receptors
might also be used to vary sensitivity to cross-
reactive TCR ligands.
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peptides bound to self-MHC. This compromise ensures
that individual TCR–pMHC interactions are rarely opti-
mal. Recent developments mean that TCRs can now be
affinity-enhanced by phage display [75], yeast display
[76] and computational design [77,78]. Such enhance-
ment has been used to build immune foresight by select-
ing TCRs that can recognize all known escape variants of
HIV [79]. Enhanced TCRs are particularly useful for can-
cer immunotherapy, as thymic selection culls T cells
whose TCRs strongly recognize self-antigens. This process
is presumably responsible for the finding that natural
anti-tumour TCRs bind with substantially weaker affinity
than anti-pathogen TCRs [80,81]. This leaves cancer-
specific T cells at a distinct disadvantage compared to
their counterparts that respond to non-self-peptides. The
enhancement processes described above can now be used
to close the TCR binding affinity gap between optimal
anti-pathogen TCRs and weaker anti-tumour TCRs.
Enhanced optimal TCRs can then be used in TCR gene
therapy for cancer [82]. Such approaches are currently
showing great promise. However, as enhanced TCRs have
not undergone the rigours of thymic selection, where cells
with TCRs that react strongly to self are deleted, they
carry an inherent, but small, risk of being autoreactive. A
recent trial of a TCR specific for the cancer-specific pro-
tein melanoma-associated antigen (MAGE) highlighted
the potential problem. When cells with an enhanced
MAGE-specific TCR were transfused back into two cancer
patients, these patients developed rapid and fatal heart
disease. Subsequent studies determined that the modified
MAGE-specific TCR was also capable of cross-reacting
with an MHC-I-presented peptide from the heart protein
titin [83,84]. Despite these teething problems, other trials
with other receptors have been successful, and we antici-
pate that the use of such therapies will become common-
place in the next 20 years. Many groups are currently
examining the use of various hybrid antigen receptors in
T cell therapy. Such strategies are beyond the scope of
this review, but have been documented recently elsewhere
[85]. Enhanced TCRs have also recently been used as
soluble molecules to induce cancer regression [86], thus
opening up a further exciting mechanism by which TCRs
can be used for therapeutic benefit (Fig. 9). The use of
TCRs as soluble ‘drugs’ does not incorporate the same
dangers as cell-based TCR therapies, as dosage can be
scaled or medication withdrawn if difficulties arise. The
potential for commercial use of TCRs has been assessed
elsewhere [87].
Unconventional T cells
The list of unconventional T cells that do not recognize
pMHC ligands is growing steadily, further demonstrating
the versatility of the TCR. Recent discoveries have high-
lighted the existence of ab T cells that recognize non-
peptide ligands. Approximately 10% of all ab T cells are
now thought to recognize lipid antigens. A further 10% of
human ab T cells appear to recognize bacterial metabolites.
ab TCR recognition of lipids
Many human ab T cells have been identified recently
that respond to non-peptide antigens presented by MHC
class I-related molecules from the CD1 protein family
[88]. These glycoproteins are ideally suited for presenta-
tion of lipid-based antigens to T cells due to the hydro-
phobic nature of their deep antigen-binding pockets.
There are five isoforms of CD1 molecules in humans,
CD1a–e, although CD1e is not involved in antigen pre-
sentation. The antigen-binding clefts of CD1a–d differ in
shape and size permitting the presentation of different
lipids to T cells (Fig.10). T cells restricted by the group
1 CD1 molecules (CD1a–c) are considerably more
numeric than CD1d-restricted T cells, but far less is
known about these T cells and the TCRs that they
Fig. 8. T cell cross-reactivity causes
autoimmunity. T cells bearing autoreactive T cell
receptors (TCRs) sometimes escape from thymic
culling and populate the peripheral tissues. Such
cells usually bear TCRs that bind very weakly to
self-peptide and generally remain harmless.
However, if such a T cell becomes activated in
response to a pathogen-derived peptide it will be
stimulated to become an effector T cell. Antigen-
experienced cells are known to be more sensitive
to TCR triggering. Activation of such cells by a
cross-recognized self-peptide could then result in
autoimmune attack.
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express. At the time of writing, structures of group
1 CD1-restricted TCRs in complex with their antigen are
only just starting to emerge. It is expected that further
structures will appear soon in the literature.
CD1d–lipid complexes bind to TCRs that are expressed
by the innate-like NK T cells [93]. CD1d-restricted T cells
are divided into two types based on their TCR gene usage
and the antigens to which they respond. Human type I
NK T cells respond strongly to the lipid a-GalCer. These
T cells typically utilize a semi-invariant TCR, and have
been termed iNK T cells to reflect this. The type I NK T
TCR uses an invariant TCR-a chain (TRAV10/TRAJ18)
paired with a TRBV25.1-encoded b chain. Type II NK T
cells express a broader TCR repertoire and are not acti-
vated by a-GalCer. NK T TCR recognition appears to be
far more rigid than that observed for conventional recog-
nition of pMHC. Type I NK T TCRs adopts a common
footprint on CD1d (Fig. 11a). This recognition has been
compared to an innate pattern recognition receptor.
Recent type II NK T TCR–CD1d–sulphatide and lysosul-
phatide complexes have revealed that the mode of type II
NK T TCR recognition is different to type I NK T TCR
recognition [97]. Type II NK T cells dock orthogonally
and over the A0-pocket of CD1d and make a larger bind-
ing interface than type I NK T TCRs. The binding mode
of type II NK T TCRs is closer to that used by conven-
tional TCR docking on pMHC.
GEM T cells recognize mycobacteria-derived (glyco)-
lipids in the context of CD1b, a molecule which has the
potential to accommodate the largest and most diverse
lipid ligands among the CD1 protein family [90]. Although
no ternary structure of a TCR bound to the CD1b–lipid
complex has been resolved so far, a recent study suggested
that binding of the lipid antigen to CD1b could induce a
conformational change of the latter. Thus, the TCR recog-
nition would be mediated not only by the solvent-exposed
polar headgroup of the lipid, but also by the rearranged res-
idues from the antigen-presenting molecule [90]. CD1c is
also capable of presenting mycobacterial lipids and lipo-
peptides [98]. Similarly to CD1b, TCR recognition of CD1c
seems to be mediated by both the lipid antigen and CD1c
residues; however, without showing a common pattern rec-
ognised by all TCRs responding to the same antigen [91].
Interestingly, CD1c can also present immunogenic self-
derived lipids accumulated in leukaemia cells, contributing
to ab T cell-mediated tumour surveillance [99].
Contrary to CD1b–d, CD1a can bind lipids lacking a
polar headgroup. These hydrophobic lipid antigens are
then not recognized directly by the TCR, but rather allow
CD1a to adapt to a TCR-activating conformation [89]
(Fig. 11b). In contrast, lipids containing a polar head-
group can also be bound by CD1a but disrupt the acti-
vating conformation of the antigen-presenting molecule,
thus abolishing TCR-mediated recognition.
MR1-restricted ab TCRs
It has been shown recently that MAIT cells recognize
intermediates in the riboflavin biosynthesis pathway
Fig. 9. Soluble T cell receptor (TCR) therapy. (a) The MHC-I
antigen presentation pathway is predicted to present at least one
peptide from any protein present in a cell at 500 copies or more.
This clever system allows the TCRs on the surface of MHC-I-
restricted T cells to inspect the cellular proteome from the cell
surface and detect internal anomalies. This ‘X-ray vision’ allows
TCRs to access a far greater number of cellular targets than are
available to monoclonal antibodies. Phage-display and directed
evolution of TCRs [75] can generate very high-affinity molecules
(KD < 10 pM) that bind to the cognate peptide-MHC (pMHC) with
very long half-lives (several hours). These molecules can then be
used to deliver therapeutic payloads to specific cells in vivo. (b)
High-affinity tumour-specific TCRs can be ‘fused’ to a CD3-specific
Fab fragment to produce a bi-specific molecule. Such molecules have
recently been used to induce cancer regression [86].
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bound to the MHC-like molecule MR1 [100–102]. MAIT
cells constitute about 10% of all T cells in humans, so
recognition is likely to represent the most dominant of all
T cell antigen-specificities. Vitamin B is synthesized by
some bacteria and yeast but not by mammals. Thus, such
microbial-specific biosynthetic pathways provide a further
mechanism that T cells can use to distinguish self from
non-self. MAIT TCRs bind to riboflavin precursors and
the presenting MR1 molecule (Fig. 11c). Interestingly,
MR1 can also present non-activating metabolites belonging
to the vitamin B group, namely folic acid derivatives. The
invariant TCR-a chain binds MR1 in a conserved, innate-
like manner, thus allowing the TCR to interact directly
with the activating riboflavin precursor, while no such con-
tact is made if the MR1-bound ligand is a folic acid deriv-
ative [95,103]. MAIT cells have set a new paradigm in T
cell recognition. As yet it is unclear how many other bacte-
rial metabolites can be recognized by T cells, as a recent
study by Corbett et al. [104] showed that MR1 is capable
of capturing and presenting unstable intermediates of ribo-
flavin synthesis, which would otherwise be converted into
non-activating metabolites. However, it is established that
the dominant subset of gd T cells in human peripheral
blood recognize intermediates in the non-mevalonate
microbial pathway of isoprenoid biosynthesis, so it remains
possible that a sizable fraction of human T cells also target
other microbial-specific synthetic pathways.
gd TCRs
Surprisingly little is known about human gd T cells or
the ligands they recognize. Unlike ab T cells, gd T cells
exhibit strict tissue-specific localization, which is deter-
mined by the identity of the rearranged TCR. This is
because gene rearrangement at the trg and trd loci is pro-
grammed developmentally and different gd T cells carry-
ing distinct TCR-g and TCR-d rearrangements arise in
successive waves that colonize different tissues during
embryonic development [105]. The tissue specificity of
gd T cells may also reflect a difference in the expression
of gd TCR ligands. Should this prove true, then gd TCRs
and their ligands might become very useful for tissue
Fig. 10. CD1a–d presentation of lipids. (a) CD1a can bind lipids not endowed with polar headgroups. Such lipids do not disrupt the T cell
receptor (TCR)-activating conformation of the CD1a molecule. The presented ligand is lysophosphatidylcholine (LPC) [Protein Data Bank
(PDB): 4X6E] [89]. (b) CD1b can potentially present the largest and most diverse lipids of all CD1-family proteins. The lipid ligands can possess
one, two or three alkyl chains buried in the hydrophobic pockets of CD1b while their polar headgroup can be recognized by germline-encoded
mycolyl-reactive (GEM) T cells. The presented ligand is ganglioside GM2 (PDB: 1GZP) [90]. (c) CD1c can present mycobacterial lipids such as
phosphomycoketide (shown) to ab T cells (PDB: 4ONO) [91]. (d) CD1d can present self-derived lipids such as sulphatide (shown) or a-
galactosylceramide (a-GalCer) to both ab [type I and II natural killer (NK) T cells] and gd T cells (PDB: 4MQ7) [92].
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targeting. It remains to be seen whether gd TCRs can
ever bind to pMHC ligands. Nevertheless, structural stud-
ies of the complex between a murine gd TCR and an
MHC class I-like molecule T22 (Fig. 11f) indicate that at
least some gd TCRs can bind their ligand in a manner
reminiscent of ab TCR–MHC interactions [96,106].
Most progress with gd TCRs has been made with the
predominant subset of gd T cells found in human periph-
eral blood that express a TCR made from the Vg9 and Vd2
genes. Vg91Vd21 T cells have been shown to recognize
small pyrophosphate intermediates of the lipid biosynthetic
pathway used by some bacteria [107,108]. Notably, pyro-
phosphate antigens can accumulate in neoplastic cells as
well, as a result of metabolic deregulation [109]. While the
structure of a Vg9Vd2 TCR has been solved [110], there is
not yet a structure of this TCR bound to its ligand. Recog-
nition of pyrophosphate ligands requires cellular presenta-
tion by a primate cell [111]. This species specificity
suggested that pyrophosphate antigens might be presented
to Vg91Vd21 T cells by an MHC-like molecule. Recently
the candidate for a pyrophosphate antigen-presenting mol-
ecule has been narrowed down to butyrophilin 3A1
(BTN3A1), an immunoglobulin-like molecule encoded in
the MHC I locus. Crystallographic studies revealed that
pyrophosphate antigens can be bound either in a shallow
extracellular pocket of BTN3A1 and presented directly to T
cells [112] or in an intracellular domain, enforcing a TCR-
activating conformational change of the presenting mole-
cule [113]. These mechanisms, however, are not necessarily
mutually exclusive, as both intra- and extracellular binding
of phosphoantigens may be required for efficient TCR
recognition.
Fig. 11. Recognition of antigen by ‘unconventional’ T cell receptors (TCRs). (a) Type I natural killer (NK) TCR recognition. The TCR binds
CD1d–a-galactosylceramide (aGalCer) in a parallel docking mode. The recognition is markedly different from any known ab TCR–peptide-
MHC (pMHC) interactions [Protein Data Bank (PDB): 3VWK] [94]. (b) Recognition of CD1a-lipid complex. ab TCR recognizes a permissive
conformation of CD1a surface that depends on the nature of the lipid ligand bound by the latter. Contrary to TCR-CD1d structures, no direct
interactions between TCR and a lipid ligand bound to CD1a have been observed (PDB: 4X6C) [89]. (c) Mucosal-associated invariant T (MAIT)
TCR recognition of MR1. MR1 can present both activating (riboflavin precursors) and non-activating (folic acid precursors) intermediates from
vitamin B biosynthetic pathways. The recognition of MR1 is mediated by conserved, invariant residues in an innate-like manner. The activating
metabolites directly contact the TCR while no such interactions are observed for the non-activating metabolites (PDB: 4L4V) [95]. (d) A hybrid
d/ab TCR binds the CD1d-aGalCer complex. The TCR is composed of a variable Vd1 domain fused with joining and constant a domains, and
paired to a TCR-b chain. TCR-CD1d interactions are driven mainly by the germline-encoded Vd1 residues while TCR-b mediates specific lipid
recognition (PDB: 4WO4) [7]. (e) The gd TCR recognizes CD1d–lipid complexes. Germline-encoded Vd1 residues are responsible for CD1d
binding while the lipid ligand recognition is fine-tuned by hypervariable complementarity-determining region (CDR) 3 loops (PDB: 4MNG)
[92]. (f) A mouse gd TCR binds the MHC-like molecule T22. The binding occurs predominantly via a conserved motif within the hypervariable
CDR3d loop, whereas the non-conserved CDR3d residues fine-tune the affinity of the receptor towards T22 (PDB: 1YPZ) [96].
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Similarly to ‘unconventional’ ab TCRs, gd TCRs can
mediate recognition of lipids in the context of CD1d
[92]. However, the docking manner differed substantially
from type I and II NK T cells (Fig. 11e). Importantly, the
contacts with CD1d were mediated mainly via germline-
encoded residues in CDR1 and 2 loops, while hypervari-
able CDR3 loops bound the presented lipid. Therefore, it
is possible that gd TCR can distinguish between subtly
different lipid cargoes bound to CD1d in an adaptive-like
manner. Additionally, Willcox et al. [107] have demon-
strated recently that gd TCRs can bind a ligand shared by
cytomegalovirus-infected and malignantly transformed
cells, namely endothelial protein C receptor (EPCR).
EPRC shows homology with CD1 protein family at the
level of amino acid sequence and structure, and is also
capable of presenting lipids – however, the binding of the
TCR to EPCR was lipid-independent (Fig. 12). The recog-
nition was mediated via the hypervariable CDR3g loop of
the TCR, thus suggesting that EPCR binding was a part
of an adaptive response rather than innate-like pattern
recognition. Notably, EPCR was essential, but not suffi-
cient, for the recognition of the target cells, highlighting
the need for additional accessory molecules that would
create a generalized cellular stress context. The identity of
these accessory molecules on the T cell or target cell
remains largely unknown.
EPCR is not the only example of a gd TCR ligand rec-
ognized in a cellular stress context. It has been known for
some time that a portion of human gd T cells can bind
MHC class I polypeptide-related sequence (MIC) A
[114], a stress-related ligand of natural killer cells, and
human homologue of the bacterial MutS protein
(hMSH2) [115], an element of the DNA repair system.
Both molecules can be up-regulated and expressed
Fig. 12. The versatility of the human T cell receptor (TCR). The ab TCR can engage intermediates in riboflavin biosynthesis in the context of
MR1 and a variety of lipid molecules bound to CD1a, CD1b, CD1c and CD1d. Classically, this receptor is also capable of binding to the almost
infinite array of different peptides bound to more than 12 000 human leucocyte antigen (HLA) alleles of the HLA-A, -B, -C, -DR, -DQ and -DP
loci. gd TCRs can also bind to CD1d-lipid complexes [103,108] and a variety of ectopically expressed cell stress markers including endothelial
protein C receptor (EPCR) [107] (shown), MIC A/B [114] and hMSH2 [115]. Murine gd TCRs bind to the MHC-I like molecules T10 and T22
that are not found in humans [96]. The best-studied set of human gd T cells express Vg9Vd2 TCRs and recognize pyrophosphate antigens in the
context of an immunoglobulin-like molecule, butyrophillin 3A1 [112]. The exact mechanism by which these TCRs recognize phosphoantigens
awaits a TCR-ligand structure.
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ectopically upon DNA damage, oxidative stress, malignant
transformation and Epstein–Barr virus infection
[116–118]. Importantly, both MIC A [119] and hMSH2
[116] were dually recognized by the TCR and a natural
killer receptor NKG2D. Biophysical studies indicated that
the ligand (MIC A) was bound initially by NKG2D form-
ing a transient complex, giving way to a more stable
TCR–ligand complex [119]. It is therefore possible that
this sequential recognition forms a critical part of
immune surveillance, allowing the T cells to detect signs of
cellular stress rapidly which could, in turn, indicate virally
infected or transformed cells. The requirement for a multi-
component stress signature could also serve as a preventive
measure against triggering autoimmune reactions – a mat-
ter of particular importance when one considers that most
of the known gd TCR ligands are essentially self-derived.
In line with this fact, gd T cells have been shown to con-
tribute to autoimmune diseases such as myositis and type I
diabetes, as they can recognize aminoacyl-tRNA synthetases
[120] and an insulin-derived peptide [121], respectively.
The role of gd T cells in pathogenesis of autoimmune dis-
eases has been reviewed recently elsewhere [122].
Summary
It has been known for several decades that the vast major-
ity of TCRs recognize MHC-bound peptides. Recent devel-
opments have highlighted the astonishing versatility of this
receptor (Fig. 12). Indeed, it is now widely accepted that a
substantial fraction of T cell pool is dedicated to the recog-
nition of non-MHC ligands. This includes recognition of
various foreign lipids and metabolic intermediates and
stress-related proteins. However, in the case of gd T cells,
the identity of putative ligands remains largely unknown.
Although monoclonal antibodies now account for almost
half of the new drugs that come onto the market, several
TCR-based therapeutic strategies are in development. Such
strategies are likely to have a bright future, and further
exciting advances are anticipated shortly.
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